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Tumor infiltrating stem cells have been suggested as a vehicle for the delivery of a suicide gene towards otherwise difficult to treat
tumors like glioma. We have used herpes simplex virus thymidine kinase expressing human multipotent adult progenitor cells
in two brain tumor models (hU87 and Hs683) in immune-compromised mice. In order to determine the best time point for the
administration of the codrug ganciclovir, the stem cell distribution and viability were monitored in vivo using bioluminescence
(BLI) andmagnetic resonance imaging (MRI). Treatment was assessed by in vivo BLI andMRI of the tumors.We were able to show
that suicide gene therapy using HSV-tk expressing stem cells can be followed in vivo by MRI and BLI. This has the advantage that
(1) outliers can be detected earlier, (2) GCV treatment can be initiated based on stem cell distribution rather than on empirical time
points, and (3) a more thorough follow-up can be provided prior to and after treatment of these animals. In contrast to rodent stem
cell and tumor models, treatment success was limited in our model using human cell lines. This was most likely due to the lack of
immune components in the immune-compromised rodents.
1. Introduction
Gliomas are themost common brain tumors in humans.They
comprise a broad range of lesions with distinct differences
in malignancy, which is assessed according to the World
Health Organization classification [1]. Glioblastoma multi-
forme (GBM) is the most malignant glioma with a dismal
prognosis despite the advantages in conventional therapy
including complete surgical resection, chemotherapy, and
radiotherapy [2, 3]. Tumor relapse ismainly due to infiltration
of tumor cells into normal brain tissue and the presence
of cancer stem cell populations [4–7]. In recent year, novel
experimental treatment options have been considered and
explored [3]. Gene therapy using viral vectors to transduce
tumor cells with therapeutic genes is an attractive alter-
native to conventional therapy. Hereby, approaches range
from mutation correction, enhancement of the immune
response against tumor cells, RNA interference, and targeted
lysis of tumor cells using selective replicative viruses, to
antiangiogenic and suicide gene therapies [8, 9]. Several
suicide genes have been tested successfully in experimental
models. Hereby, the most extensively studied systems are the
herpes simplex virus thymidine kinase gene (HSV-tk) with
the prodrug ganciclovir (GCV) and the cytosine deaminase
gene, which converts 5-fluorocytosine into the cytotoxic 5-
fluorouracil [9, 10]. As infiltration of glioma cells into normal
brain tissue makes delivery of the suicide gene difficult, new
options have been explored to target these infiltrating cells
[6, 11–13]. Hereby, neural and mesenchymal stem cells are a
suitable vehicle for the suicide gene as these cells have the
ability to migrate to malignant gliomas and track infiltrating
tumor cells [5, 14–17].
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Figure 1: Concept of tumor therapy by using suicide gene expressing
stem cells that are able to track tumor cells. It has been shown
that certain stem cells are able to track infiltrating tumor cells
[5, 14–17, 22]. In addition, the therapeutic cells must carry a
suicide gene, in this case the herpes simplex virus thymidine kinase
(HSV-TK). When a substrate for the HSV-TK enzyme, ganciclovir
(GCV), is provided, it enters the cell and is converted by HSV-
TK into GCV-monophosphate. The HSV-TK displays a 1000-fold
higher affinity for GCV than the mammalian thymidine kinase so
that systemic toxicity is limited while the increased affinity boosts
tumor therapy capabilities [5]. Cellular kinases will phosphorylate
the GCV-monophosphate further to GCV-triphosphate, a guanine
nucleoside analogue which inhibits cellular DNA polymerase and
results in chain termination with subsequent cell death. While this
would erase the therapeutic cell but not the targeted tumor cell,
a means for transferring the cytotoxic compound to the tumor
cell is required. GCV-monophosphate can passively diffuse into
neighboring cells after the formation of gap junctions between
adjacent cells, which results mostly in tumor and therapeutic cell
killing as normal adult brain cells usually do not replicate [36]. This
is also known as “the bystander killing effect” [18, 37].This approach
can in theory terminate both primary and infiltrating tumor cells,
thus eliminating sources of possible recurrent tumors [5].
This approach relies on the administration of cells car-
rying a suicide gene, such as HSV-tk. When a substrate like
GCV is provided, it enters the cell and is converted by HSV-
TK into GVC-monophosphate [6]. Subsequently, cellular
kinases recognize the monophosphate and will create GCV-
triphosphate, a guanine nucleoside analogue which causes
DNA chain termination and subsequent cell death.
Due to the formation of gap junctions between adjacent
cells [18–20], GCV-monophosphate can passively diffuse into
neighboring cells, which will mainly result in tumor and
therapeutic cell killing as normal adult brain cells do not
replicate. This is also called bystander killing effect (see also
Figure 1) as tumor and therapeutic cells will be terminated.
When using stem cells that can track infiltrating tumor
cells, this method can in theory be applied not only to
remove the main tumor but also to destroy any remaining
tumor cells, thus eliminating sources of possible tumor recur-
rence [6]. Hereby, therapeutic cells are also eliminated after
GCVadministration, suppressing possible adverse effects like
uncontrolled stem cell proliferation [21]. The feasibility of
this strategy was demonstrated by several groups in both
xenograft and syngeneic animal models [5, 21, 22].
Not only do noninvasive imaging strategies play an
important role for the diagnosis and grading of brain tumors
in humans [23–26], but they are also essential to follow
up and assess the success of therapy in vivo [24]. This is
important not only in the clinic but also for the assessment of
experimental models. In contrast to diagnostic imaging pro-
cedures like magnetic resonance imaging (MRI) or positron
emission tomography (PET), a wider range of imaging
methods is available for preclinical research. In particular,
optical imagingmethods with limited depth penetration, like
bioluminescence imaging (BLI) or fluorescent imaging, are
extremely valuable in mouse tumor models as they are cost
efficient and allow the monitoring of cell viability and gene
expression [27–29]. In the field of (stem) cell research, it is
also of advantage to monitor the location, viability, and gene
expression of the therapeutic cells. Hereby, MRI, PET, and
BLI are most frequently used [29, 30].
Previously, we have shown that suicide gene therapy
using HSV-tk expressing mouse Oct4− bone marrow derived
multipotent adult progenitor cells (mOct4− BM-MAPCs) as
cellular vehicles can be validated by multimodal imaging
using MRI and BLI [17]. Hereby, in vivo imaging methods
were suitable not only for assessing therapy outcome but also
for making therapeutic decisions. For example, if GCV is
administered before stem cells have migrated towards the
tumor cells, therapy may fail due to premature killing of
the therapeutic cells. In the current study, it was our aim to
validate this concept in experimental human glioma models
(hU87 andHs683) using therapeutic humanmultipotent pro-
genitor cells (hMultistem) in immune-compromised animals.
The distribution of stem cells labeledwith superparamagnetic
iron oxide particles (SPIO) was followed up by MRI. Their
viability and suicide gene expression were assessed by using
transgenic cells that express the firefly luciferase (fLuc) gene
and the HSV-tk gene, respectively. Treatment was validated
by monitoring the tumor volume (MRI) and tumor cell
viability of Renilla Luciferase (rLuc) expressing hU87 or
Hs683 glioma cells.
2. Materials and Methods
2.1. Cell Culture. The human bone marrow derived stem
cell line hMultistem was obtained from ReGenesys BVBA
(Heverlee, Belgium). The cells were cultured as described
previously [31]. Cells were cultured at densities of 2 ×
103 cells/cm2.
The human brain tumor cell lines hU87 and Hs683
were obtained from the ATCC (Molsheim, France) and the
laboratory of Dr. R. Kiss (Universite Libre de Bruxelles,
Brussels, Belgium), respectively. The hU87 cell line was
cultured using Eagle’s Minimum Essential Medium (EMEM,
Gibco Invitrogen) supplementedwith 10% fetal bovine serum
(FCS). Hs683 cells were cultured using RPMI 1640 (Gibco
Invitrogen) supplemented with 10% FCS, 0.2% L-glutamine
(Gibco Invitrogen), 100 units penicillin, 100 𝜇g streptomycin
(Cellgro), and gentamycin (50 𝜇g/mL, Gibco Invitrogen).
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2.2. Cell Transduction. Lentiviral vectors were provided by
the Viral Vector Core,Molecular Virology andGeneTherapy,
KU Leuven. hMultistem cells were consecutively transduced
(p24 = 20 pg p24/cell) with two lentiviral vectors with an
EF1𝛼 promoter [21]. First, a lentiviral vector encoding the
eGFP gene and a puromycin resistance cassette were used
to transduce the cells (LV-EF1𝛼-eGFP-IRES-PuroR). Cells
were split twice to allow the sufficient cell growth and trans-
gene expression before selecting the cells using increasing
concentrations of puromycin (2–8𝜇gmL−1, Sigma-Aldrich,
St. Louis, MO, USA). A second lentiviral vector encod-
ing the fLuc, HSV-tk, and blasticidin resistance cassette
genes was used to again transduce the cells (LV-EF1𝛼-
3flag-fLuc-T2A-HSV-TK-IRES-BsdR). Afterwards, cells were
split twice before selection commenced using increasing
blasticidin concentrations (20–80 𝜇gmL−1, Invivogen, San
Diego, USA). Control cells were generated by adopting a sim-
ilar strategy using the LV-EF1𝛼-3flag-fLuc-T2A-eGFP-IRES-
BsdR.
The human tumor cell lines hU87 and Hs683 were
transduced using a CMV promoter driven lentiviral vector,
which encodes for mCherry and rLuc. 1.25 × 104/cm2 tumor
cells were seeded and allowed to attach prior to transduction.
Cells were incubated (108 pg p24/cell) with a CMV promoter
driven lentiviral vector (provided by the Viral Vector Core,
KU Leuven, Belgium) encoding for mCherry, rLuc, and a
blasticidin resistance cassette for 24 hours. Subsequently, cells
were washed and expanded. Approximately one week after
transduction, mCherry expression became apparent. At that
time, blasticidin selection commenced and was maintained
for one week (40–60𝜇g/mL). 2.5 × 104 cells were seeded per
well and allowed to attach after which rLuc BLI (IVIS 100
system, Perkin Elmer) was performed using coelenterazine-h
(Rediject Coelenterazine-h, Perkin Elmer, 0.25𝜇g/well) as a
substrate.
2.3. In Vitro Confirmation of Transduction. For the hMulti-
stem cells, eGFP expression was used for visual confirmation
of transduction after which fLuc andHSV-tk expression were
assessed. For fLuc expression, 100.000 cells were seeded in
triplicate in a 24-well plate and were allowed to attach before
BLI measurements were performed. An amount of 75𝜇g of
D-luciferin (Promega, Madison, WI, USA) was added per
well prior to BLI experiments using an IVIS 100 system
(Perkin Elmer, Waltham, MA, USA). The temperature was
maintained at 37∘C. Scanning parameters included medium
binning, f stop = 1, time = 10 s or 1min. Data were analyzed
by using the living image 2.50.1 software. Similarly, mCherry
expression was used for the tumor cell lines in order to
confirm transduction by fluorescence microscopy. BLI was
performed using the rLuc substrate coelenterazine-h (Redi-
ject Coelenterazine-h, Perkin Elmer, 0.25 𝜇g/well).
HSV-tk expression was confirmed with a GCV killing
experiment. Hereby, 20.000 cells were seeded in a 24-well
plate and were allowed to grow. The following day, ganci-
clovir (Cymevene, Roche, Basel, Switzerland) was added in
different concentrations (100𝜇M, 1 𝜇M, and 0.01𝜇M) for four
consecutive days, after which BLI was performed. Cells were
subsequently collected and a BCA protein assay (Thermo
Scientific, Rockford, USA) was performed.
2.4. Cell Labeling with Superparamagnetic Iron Oxide Particles
(SPIO) Labeling. hMultistem cells were labeled for 24 hours
with in-house produced superparamagnetic iron oxide par-
ticles (SPIO) (seed-mediated growth; silane-functionalized
and PEGylated (SMG2-mPEGSi) nanoparticles with a diam-
eter of approximately 13 nm; 20𝜇g iron/mL medium) in
combination with poly-L-lysine (1.5𝜇g/mL) [32, 33]. Subse-
quently, cells were washed three times and kept overnight in
freshmedium after which 1× 105 cells were harvested forMRI
and 5 × 104 cells were harvested for ICP-OES measurements
(for more details, see also [32, 33]). MRI agar phantoms
containing 500 cells 𝜇L−1 were prepared to validate MRI
detectability limits. In vitro T∗
2
-weighted MR images were
acquired (parameters: multigradient echo pulse sequence,
repetition time (TR): 1500ms, first echo time (TE): 4.44ms
with 8 increments of 6.75ms, matrix size: 400 × 400, in plane
resolution: 18.7 𝜇m2, slice thickness: 0.35mm, and number of
slices: 12).
2.5. Tumor Models: Stereotactic Cell Injection. All animal
experiments were conducted according to the European
Union Community Council guidelines and were approved
by the local ethics committee of KU Leuven. Before
surgery, animals were anaesthetized by an i.p. injection
with a mixture of ketamine (4.5mg/kg, Ceva, Pompidou,
France)/medetomidine (0.6mg/kg, Domitor, Pfizer, New
York, USA). Local analgesia (2% xylocaine, AstraZeneca,
London, UK) and antibiotics (6mg/mouse, Ampiveto-20,
200mg/ml, VMD, New Haw, Surrey, UK) were administered
prior to surgery. After fixation of the animals in a stereotactic
frame adapted with a quintessential stereotaxic injector
(Stoelting, Wood Dale, USA), Hs683 or hU87 tumor cells
were resuspended in 5 𝜇L PBS and injected (0.5𝜇Lmin−1)
into the right striatum of nude Hsd:Athymic-Foxn1nu mice
using a 10 𝜇L Hamilton syringe, equipped with a 22G needle.
The following coordinates were chosen for cell injection:
0.5mm anteriorly, 2.0mm lateral to bregma, and 3.0mm
from the dura. Anesthesia was reversed using Antisedan
(0.015mg/animal, Pfizer Animal Health, Terre Haute, Indi-
ana, USA). The number of animals is indicated in the
respective figure legends.
2.6. Tumor Models (hU87 and Hs683): Suicide Gene Therapy.
After injection of 3 × 105 hU87 or 5 × 104 Hs683 cells in the
striatum of nude Hsd:Athymic-Foxn1nu mice, tumors grew
for one (hU87) or two (Hs683) weeks prior to stereotactic
intratumor injection of 5 × 105 labeled and transduced
hMultistem cells. Two weeks after tumor induction, three
experimental groups were generated: (1) sham operated
animals receiving no cells (PBS injection), (2) PBS treated
control animals receiving 5 × 105 hMultistems and treatment
with PBS injections, and (3) GCV treated animals also
receiving 5 × 105 hMultistems but also treatment with GCV.
Treatment (GCV (50mg/kg) or PBS) was administered for
14 consecutive days starting at day 1 after hMultistem cell
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injection. At the end of PBS/GCV administration, both MRI
and BLI were performed to assess tumor response and cell
viability, respectively. Of the injected hMultistem cells, only
1% of cells were labeled with SPIO to reduce imaging artifacts
[17]. Imaging was performed prior (MRI) to and following
hMultistem injection (MRI/BLI). At the end of treatment,
both MRI and BLI were performed to assess tumor response
and hMultistem viability, respectively.
2.7. Imaging:MRI. AllMR imageswere acquired using a 9.4 T
BioSpec small animalMR scanner (Bruker Biospin, Ettlingen,
GE) equipped with a horizontal bore magnet and an actively
shielded gradient set of 600mTm−1 (117mm inner diameter)
using a 7 cm linearly polarized resonator for transmission
and an actively decoupled dedicated mouse surface coil for
receiving (Rapid Biomedical, Rimpar, Germany). MRI was
performed after tumor induction, prior to and following stem
cell injection but before treatment initiation, and at the end
of the treatment. Prior to scanning, mice were anaesthetized
with 2% isoflurane for induction and 1.5% isoflurane for
maintenance, respectively. Temperature and respiration were
monitored throughout the experiment and maintained at
37∘C and 100–120 breaths/minute. For in vivo tracking of
the SPIO labeled hMultistem cells, 3D T∗
2
-weighted MR
images (FLASH sequence, TR: 100ms, TE: 12ms, flip angle:
20∘, resolution: 0.0078 cm/pixel, and field of view: 2.0 ×
1.5 × 0.75 cm) were acquired and analyzed with the ImageJ
software (National Institute of Health, Bethesda, Maryland,
USA) to calculate the hypointense pixel volume. Further-
more, T
2
-weighted axial (RARE sequence, TR: 3157.6ms, TE:
48.8ms, matrix size: 256, FOV, 2.5 cm, in plane resolution:
0.0078 cm/pixel, number of slices: 24, and slice thickness:
0.05 cm) and coronal (RARE sequence, TR: 3000ms, TE:
50.2ms, matrix size: 256, FOV: 2.5 cm, number of slices: 15,
and in plane resolution: 0.0078 cm/pixel) MRI scans were
acquired to follow up tumor size. The area of the lesion was
determined by outlining it manually on all slices using the 5.1
Paravision software (Bruker, Biospin). The sum of the cross-
sectional area was used to determine the total tumor size.
An ANOVA test (GraphPad PRISM, GraphPad Software, La
Jolla, CA, USA) was used to determine significant differences
with𝑝 < 0.05. To validate the integrity of the blood-brain bar-
rier (BBB), pre- and postcontrast (Dotarem (100𝜇L/mouse
of 0.05mmol/mL, i.v.), Guerbet, Villepinte, France) T
1
-
weighted MR images were acquired (RARE sequence, TR:
819ms, TE: 7.6ms, matrix size: 256, FOV: 2 cm, number
of slices: 20, and in plane resolution: 0.0078 cm/pixel). For
statistical analysis of the blood-brain barrier integrity, the
percentage of increase following Dotarem injection was
calculated as previously described [34].
2.8. Imaging: BLI. Mice were anesthetized with isoflurane
(2% induction, 1.5%maintenance) and placed in the IVIS 100
optical imaging system (Perkin Elmer), maintaining the body
temperature at 37∘C. Subsequently, D-luciferin (126mg/kg,
Promega) or coelenterazine-h (15𝜇g/mouse, Perkin Elmer)
were intravenously injected to assess stem cell or hU87
tumor cell viability, respectively. Subsequently, biolumines-
cent images were acquired. Data were analyzed formaximum
intensity of the photon flux by the living image 2.50.1 software
(Perkin Elmer).
2.9. Humane Endpoints. Animals were sacrificed when
symptoms reached grade 3 out of 4 (grade 0 for healthy mice,
grade 1 for slight unilateral paralysis, grade 2 for moderate
unilateral paralysis and/or beginning hunchback, grade 3
for severe unilateral or bilateral paralysis and pronounced
hunchback, and grade 4 for moribund mice) [35].
2.10. Histology. Animals were sacrificed by an i.p. overdose of
Nembutal (300 𝜇L, Ceva) and subsequently perfused with 4%
ice-cold paraformaldehyde (PFA) solution (Sigma-Aldrich).
After overnight postfixation in 4% PFA, brain tissue was
stored at 4∘C in a PBS solution containing 0.1% sodium azide
(Fluka, Sigma-Aldrich). Five 𝜇m thick paraffin sections were
cut and a Masson trichrome, a Prussian blue, and an Iba1
immunostaining were performed [32]. For the latter, sections
were stained with an Iba1 antibody (1/250). Visualization was
achieved by using the Dako EnVision + system-HRP (DAB)
kit (Dako, Glostrup, Denmark).
2.11. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism (GraphPad Software PRISM, La Jolla,
CA, USA). Significant differences between GCV and PBS
treated animals regarding total tumor volumes (MRI: mm3)
and cell viability (BLI: P/s) were determined by means of 2-
way ANOVA test with differences of 𝑝 < 0.05 regarded as
significant. Figures show means ± SEM.
3. Results
The concept of the bystander killing effect using human bone
marrow derived stem cells (hMultistems) that are capable of
tracking brain tumor cells and that express a suicide gene is
illustrated in Figure 1. A multimodal imaging approach was
taken tomonitor the fate of the stem and tumor cells to assess
the success of therapy.
3.1. In Vitro Assessment of Transduction and Labeling of
hMultistem and Tumor Cells. The hMultistem cell line was
transduced with a lentiviral vector in order to express
either eGFP and fLuc (control) or eGFP, fLuc, and HSV-
TK. The eGFP expression was used for visual confirmation
of transduction after which fLuc and HSV-tk expression was
assessed. BLI of cells transduced with either eGFP-fLuc (2.71
× 106 ± 1.17 × 105) or eGFP-fLuc-HSV-tk (1.79 × 106 ± 5.83 ×
104) constructs showed a significant increased signal intensity
compared to wild type (wt) hMultistem cells (6.16 ± 1.02 ×
104) (Figure 2(a)).
Subsequently, the HSV-TK expression was assessed by
adding 0.01 𝜇M, 1 𝜇M, or 1mM GCV to the cells during four
consecutive days, which exerted a dose-dependent cell killing
effect in eGFP-fLuc-HSV-tk expressing hMultistem cells but
not in the eGFP-fLuc expressing control cells as assessed by
BLI and a BSA protein assay.
In order to follow the distribution of engrafted hMulti-
stem cells in vivo with high resolution, we decided to acquire
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Figure 2: In vitro validation of hMultistem transduction. (a) Assessment of firefly luciferase (fLuc) expression via BLI showed a significant
difference between transduced (eGFP-fLuc as well as eGFP-fLuc-HSV-tk) and wt hMultistem. (b) GCV killing experiment for validation of
HSV-tk expression. Left: BLI signal was significantly decreased in eGFP-fLuc-HSV-tk expressing cells but not in eGFP-fLuc expressing control
cells for all GCV concentrations compared to cells without GCV treatment. Right: the BCA protein assay confirmed BLI results and showed a
dose-dependent cell killing in eGFP-fLuc-HSV-tk expressing cells but not in eGFP-fLuc expressing cells. Levels of significance are expressed
as ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
3D MR images. Therefore, eGFP-fLuc-HSV-tk+ hMultistem
cells were labeled with in-house produced, biocompatible
SPIO [32]. Detailed characterization of the labeled cells
confirmed that uptake of SPIO in high quantity (TEM and
ICP-OES), resulting in sensitive detection by MRI. The BLI
signal intensity was not affected by the SPIO labeling (see
Figure 3).
In order to follow tumor growths and in parallel the fLuc
expressing hMultistem cells in the hU87 model by BLI lon-
gitudinally, hU87 cells were transduced to express mCherry
and rLuc. Figure 4 indicates that the transgene expression can
be assessed by BLI in vitro.These data prove that rLuc expres-
sion is sufficiently high for detection using coelenterazine-h
but was not affected when using D-luciferin as a substrate.
This implies that it is possible to distinguish the BLI signal
originating from the hMultistem cells (fLuc-D-luciferin sys-
tem) from the signal originating from the hU87 cells (rLuc-
coelenterazine-h). To assess the transgene expression in vivo,
3 × 105 transduced hU87 cells were injected in the striatum of
nude Hsd:Athymic-FoxN1nu mice. Tumors grew rapidly with
tumor size reaching 27.6 ± 2.4mm3 by day 21 after injec-
tion (Figure 4(b)). Simultaneously, the BLI signal increased
(Figure 4(c)), indicating tumor growth with detectable BLI
signals from day 8 onwards (day one: 91.7 ± 90.7P/s).
3.2. In Vivo Validation of hMultistem Survival and Suicide
Gene Therapy. In order to validate cell survival and GCV
killing of hMultistem, 5 × 105 transduced cells were stereotac-
tically injected in the striatumofHsd:Athymic-FoxN1numice.
Subsequently, cell survival was assessed by BLI following
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Figure 3: In vitro validation of SPIO labeling of hMultistem cells. (a) ICP-OES experiments confirmed iron internalization after SPIO labeling
(10 ± 1 pg Fe cell−1) but not for unlabeled control cells. (b) Multiecho T
2
map (MRI) confirms higher relaxation rats for SPIO labeled cells
compared to controls. (c) BLI signal intensity was not significantly affected by SPIO labeling of cells (∗∗∗𝑝 < 0.001).
PBS or GCV (50mg/kg) injection for 15 days. As shown in
Figure 5, cell viability decreased independently of PBS or
GCV injection, indicating that stem cell survival is compro-
mised in the host environment. One possible explanation for
only marginal differences of BLI signal intensities between
PBS and GCV treated animals is the lack of GCV to cross an
apparently intact blood-brain barrier (BBB).
3.3. Validation of hMultistem Mediated Suicide Gene Therapy
in a Humanized Oligodendroglioma Model (Hs683). In order
to validate the crossing of GCV through the BBB in tumor
models, 5 × 105 transduced and SPIO labeled hMultistem
cells were stereotactically injected in the striatum of Hs683
tumor bearing nude Hsd:Athymic-FoxN1nu mice followed by
daily administration of PBS (control) or GCV (50mg/kg)
for 14 consecutive days. Histological, BLI, and MR images of
representative animals are shown in Figure 6.
MRI data confirmed correct administration and distri-
bution of hMultistem cells, which surrounded the tumor
lesion following stereotactic injection (Figures 6(a) and 7(a)).
BLI data confirmed that the expression of the fLuc gene
was sufficiently high for in vivo detection of the hMultistem
cells. However, only a small decrease in BLI signal intensity
was observed after GCV, but not PBS treatment (Figure 7).
No statistically significant difference in cell viability (BLI
signal intensity, Figure 7(b)) could be observed betweenGCV
treated and PBS treated animals after treatment.
Concurrent with these results, no statistically significant
differences in tumor volume were found between the sham
operated (𝑁 = 3), PBS treated (𝑁 = 6), and GCV treated
(𝑁 = 6) animals at the end of the treatment (day 31), nor
in the subsequent progression of tumor growth (Figure 7(c)).
Developing tumors showed statistically significant signal
enhancement in T
1
-weighted MR images after administra-
tion of contrast agent, confirming disruption of the blood-
brain barrier (Figure 7(d)). Histological analysis confirmed
the in vivo imaging results (Figure 6(c)). Prussian blue
staining showed iron accumulation only in PBS and GCV
treated animals, most likely arising from the SPIO labeled
stem cells. Staining with Iba I for the presence of activated
microglia was performed, which showed remarkably few
activated microglial cells inside the tumor when compared
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Figure 4: In vitro and in vivo validation of hU87 transduction with a mCherry-rLuc encoding vector. (a) In vitro analysis of mCherry-rLuc
expressing hU87 cells showing sufficient expression of rLuc for in vitro detection by BLI using coelenterazine-h as a substrate. Furthermore,
results show no statistically significant signal intensity differences after exposure of the rLuc positive hU87 cells to D-luciferin. (b) MRI-
based tumor volume measurements from hU87 tumor bearing animals showed rapid growth with tumors reaching an average tumor size of
27.6 ± 2.4mm3 at day 21 after injection. (c) BLI measurements on mCherry-rLuc positive hU87 tumor bearing mice also indicated tumor
growth over time. Levels of significance are expressed as ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
to previous results using mouse stem cells in a mouse tumor
model [17].
3.4. Validation of hMultistem Mediated Suicide Gene Therapy
in a Humanized Glioblastoma Model (hU87). One possible
reason for the partial failure of bystander mediated suicide
therapy in the Hs683 model is the fact that this model
shows only a limited disruption of the BBB (for Gd-based
chelates but not for Evans blue staining) [34]. Therefore, we
have also validated the suicide gene therapy approach using
hMultistem cells in the generally accepted hU87 glioblastoma
model of astrocytic origin.
After establishment of the tumors, 5 × 105 eGFP-fLuc-
HSV-tk expressing SPIO labeled hMultistem cells were
stereotactically injected in the striatum of mCherry-rLuc
expressing hU87 tumor bearing nude Hsd:Athymic-FoxN1nu
mice. Thereafter, PBS or GCV (50mg/kg) was administered
for 14 consecutive days.
MRI data confirmed that the distribution (MRI) and via-
bility (BLI) of hMultistem cells could be determined in vivo
following stereotactic injection. Representative images are
shown in Figure 8. Quantitative data are shown in Figure 9.
Unexpectedly, a decrease of the fLuc BLI signal intensity of
the engrafted hMultistem was seen not only for GCV treated
animals but also for the PBS treated animals, indicating
that the tumor environment may have induced cell death
of the injected hMultistem cells. The BLI signal intensity of
the rLuc expressing hU87 tumor cells showed an increase
of the BLI signal for the sham operated animals and the
PBS treated group but not for the GCV treated group when
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Figure 5: In vivo validation of BLI signal intensity and hMultistem survival in Hsd:Athymic-FoxN1nu mice. (a) Bioluminescence images of
a representative animal that received 5 × 105 hMultistems (day 1) and was treated from day 2 to day 15 with either PBS or GCV (50mg/kg).
(b) Quantification of BLI signal intensities shows that (1) the stem cells were detectable by BLI, (2) stem cell survival was reduced in the
environment of the host’s brain, and (3) no statistically significant difference in stem cell viability between the PBS andGCV receiving animals
was detected. Number of animals was 6 per group.
comparing signal intensities before and after initiation of
the treatment (Figure 9(c)), indicating decreased tumor cell
viability. However, the inhibition of tumor growth compared
to the two control groups was relatively small as also con-
firmed by the MRI-based determination of tumor volumes,
where no statistically significant differences between the
sham operated, PBS treated, and GCV treated groups were
found (Figure 9(d)). This decreased viability might however
reflect a slight increase in the size of necrotic areas, which
is difficult to assess on MRI due to T∗
2
effects caused by
bleeding and the SPIO labeled hMultistem cells. Tumors
showed statistically significant enhanced signal intensity in
T
1
-weighted MRI when comparing pre- and postcontrast
conditions (Figure 9(e)).
4. Discussion
Although numerous efforts have been made to ameliorate
the prognosis for glioblastoma patients, results have been
limited so far [38]. During the past decades, suicide gene
therapy has been investigated as a new therapeutic approach.
Unfortunately, results obtained in clinical trials have been
limited, mainly due to insufficient expression and poor
intratumoral distribution of the viral vectors encoding for
the suicide gene [39]. Therefore, HSV-tk expressing stem
cells that are able to track infiltrating tumor cells are a
promising vehicle for suicide gene delivery to the target
site [5, 6, 11–13]. Hereby, in vivo imaging methods are used
not only to assess the success of therapy but also to make
therapeutic decisions. For example, if the codrug GCV is
delivered before the therapeutic (stem) cells have reached the
targeted tumor cells, treatment might fail due to premature
termination of the therapeutic vehicle. Assessment of the
location and viability of the stem cells prior to initiation of
treatment is possible by using MRI, PET, or BLI [28–30].
In addition, tumor size and tumor cell viability can also
be assessed by using clinical (MRI, PET, and SPECT) or
experimental (BLI, photoacoustic imaging, and fluorescence
imaging) techniques [24, 25]. For stem cell based therapy
approaches, knowledge of the exact location of the tumor is
also important to guide cell engraftment. In this way, animals
can be followed longitudinally, thus reducing the number of
animals needed. Additional information can be generated to
gain a more thorough understanding of the dynamics of this
experimental glioblastoma treatment. As multiple parame-
ters have to be acquired almost simultaneously, multimodal
imaging approaches are of advantage providing additional,
clinically relevant parameters and allowing parallel monitor-
ing of different cell populations [25, 28, 29].
In this study, Hs683 and hU87 tumor bearing nude
Hsd:Athymic-FoxN1nu mice were stereotactically injected
with 5 × 105 HSV-tk/FLuc expressing and SPIO labeled
hMultistem cells for longitudinal follow-up of suicide gene
therapy. Three groups were studied, which included a sham
operated group (no stem cells), a PBS treated group (stem
cells but no codrug), and a GCV treated group (50mg kg−1
daily for 2 weeks). Based on MRI and BLI, the treatment
commenced after distribution of the therapeutic cells around
the tumor. Stem cell viability was verified by BLI before and
after treatment. The distribution of the stem cells around
the tumor was confirmed by histology. The hMultistem cell
viability decreased in both the PBS and the GCV treated
group in control animal (no tumor) and the hU87 tumor
bearing animals but only to a smaller extent in the Hs683
tumor bearing animals as assessed by BLI usingD-luciferin as
a substrate for fLuc, indicating that some of the loss of viable
stem cells can be attributed to the hostile microenvironment
in the host. No differences could be found in either tumor
model concerning tumor size between animals that were
sham operated or treated with PBS or GCV. However, there
was a stagnation of hU87 tumor growth after GCV treatment,
which was not the case in PBS treated or sham operated
animals. This therapeutic effect was detected by BLI but not
by anatomical imaging (MRI), which typically show a delayed
response to treatment effects.
When compared to animal models that used mouse or
rat tumor and stem cells [5, 17], stem cell mediated suicide
gene therapy in humanized tumor models proved much less
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Figure 6: Follow-up of suicide gene therapy using hMultistem as cellular vehicles in theHs683 oligodendrogliomamodel by usingmultimodal
in vivo imaging and histology. (a) MR images of a representative animal from the sham, PBS, and GCV treated groups show a comparable
tumor growth prior to hMultistem injection on T
2
-weightedMR images (upper row for each group).While there is little hypointense contrast
visible on 3D T∗
2
-weightedMR images (lower row for each group), the distribution of SPIO labeled hMultistem cells could clearly be detected
due to their hypointense contrast in the PBS and GCV treated group. When tumors grew larger, the hypointense voxels got more dispersed
over time. (b) BLI of representative animals.The fLuc expression of the stem cells was clearly detectable after engraftment and only diminished
after 14 days. (c) One week after the end of therapy, animals developed symptoms after which histological analysis was performed. Masson’s
trichrome staining (upper left) of all animals showed very large tumors. Prussian blue (upper right) staining was also performed which
confirmed the presence of iron in PBS and GCV treated animals. Finally, Iba1 staining (bottom) was performed which showed a predominant
absence of activated microglia in all treatment groups. Some minor microglial activation was however detectable around the tumor.
effective. There are several plausible explanations for this
failure of therapeutic response. First, developing tumors at
the time of stem cell injection were generally larger in the
hU87 and Hs683 models compared to the GL261 mouse
model, which may require the injection of more stem cells
to elicit a therapeutic response. However, at least a delay in
tumor growths should have been detected, which was only
the case in the hU87 model. Secondly, the bystander killing
effect depends on the formation of gap junctions between
adjacent cells. It has been reported that different brain tumor
cells display variable gap junction formation, which might
result in variable, cell line specific therapeutic response [20,
40]. Thirdly, the success of HSV-tk based gene therapy also
depends on the successful delivery of the codrug GCV to the
target site. After engraftment of stem cells in brains without
tumors, no difference between PBS and GCV treated animals
was seen, most likely due to the failure of GCV crossing
the BBB. Although disruption of the BBB was demonstrated
in our tumor models using Gd-based contrast agents, the
extent of the BBB disruption may still vary as demonstrated
before [34]. Finally, it is believed that the bystander killing
effect is also in part T cell mediated [41–43] which would
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Figure 7: Quantification of in vivo imaging data to monitor suicide gene therapy using hMultistem as cellular vehicles in the Hs683
oligodendrogliomamodel. (a)Quantification of the volumeof hypointense voxels in animals receiving SPIO labeled hMultistem cells indicates
sufficient contrast to detect the therapeutic cells in the Hs683 tumor model (sham (no cells): 𝑁 = 3, PBS treated:𝑁 = 6, and GCV treated:
𝑁 = 6). (b) Bioluminescent imaging data showed that the stem cells were detectable through BLI, but no statistically significant difference in
stem cell viability between the PBS and GCV receiving animals could be detected following treatment. However, there was a small decrease
in the BLI signal before and after treatment in the GCV treated group. (c) Tumor volume measurements proved no statistical differences
between sham operated, PBS treated, or GCV treated animals (green bar: hMultistem injection; red bar: duration of GCV/PBS treatment).
(d) T
1
-weightedMRI pre- and postcontrast injection showed BBB integrity loss in theHs683 tumor compared to the contralateral hemisphere
and the extracranial muscle at all time points (𝑁 = 15). Levels of significance are expressed as ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and
∗∗∗∗
𝑝 < 0.0001.
partially explain the absence of therapeutic effects in the T
cell lacking humanized mouse models. This theory is also
supported by our observation that in some cases PBS treated
GL261 tumor bearing animals, which received m-Oct4(−)-
BM-MAPCs, also show a decreased tumor growth evenwhen
clear tumor growth was present at the time of stem cell
injection [17].
Our results indicate that although stem cell based suicide
gene therapy is a promising approach, further investigations
are required to better understand possible mechanisms of
action in different tumor environments using a variety of
stem cells and host environments to optimize the therapeutic
effect. In order to better understand the role of the immune
system in our model system, it would be advisable to further
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Figure 8: Follow-up of suicide gene therapy using hMultistem as cellular vehicles in the hU87 glioma model by using multimodal in vivo
imaging and histology. (a) MR images of a representative animal from the sham, PBS, and GCV treated groups show a comparable tumor
growth prior to hMultistem injection on T
2
-weightedMR images (upper row for each group).While there is little hypointense contrast visible
on 3D T∗
2
-weighted MR images (lower row for each group), the distribution of SPIO labeled hMultistem cells could clearly be detected due
to their hypointense contrast in the PBS and GCV treated group (one day after engraftment). The contrast distribution changed only very
little until the end of treatment. When tumors grew larger, the hypointense voxels got more dispersed over time. (b) Left: bioluminescent
imaging using D-luciferin as a substrate for fLuc expressing hMultistem cells. Stem cells were detectable after engraftment but not after
the end of treatment for both, the PBS and GCV receiving groups. Right: bioluminescence imaging using coelenterazine-h as a substrate
for rLuc expressing hU87 tumor cells. The signal intensity increased for the sham and PBS group but not for the GCV group, indicating
some inhibition of tumor growth. (c) Two weeks after the end of therapy, animals developed symptoms after which histological analysis was
performed. Masson’s trichrome staining (upper left) of all animals showed large, dense tumors. Prussian blue (upper right) staining was also
performed which confirmed the presence of iron in PBS and GCV treated animals. Finally, Iba1 staining (bottom) was performed which
showed a predominant absence of activated microglia in all treatment groups.
study the successful m-Oct4(−)-BM-MAPCs/GL261 system
inmice with a compromised immune system.With the devel-
opment of the mentioned imaging techniques, it is now pos-
sible to monitor dynamic changes in different model systems
longitudinally in vivo, providing a rapid screening approach
to optimize stem cell therapy in malignant glioma models.
In conclusion, we have shown that suicide gene therapy
using hMultistem as cellular carriers can bemonitored in vivo
by MRI and BLI. Hereby, MRI can be used to ascertain stem
cell location prior to treatment initiation and tumor growth
follow-up. BLI can be used to assess stem cell and tumor cell
viability prior to and following treatment. Thus, outliers can
be detected earlier, GCV treatment can be initiated based on
stem cell distribution rather than on empirical time points,
and a more thorough follow-up is possible prior to and
following treatment of these animals.This will hopefully lead
to a better understanding and optimization of a promising
therapeutic approach for glioblastoma patients.
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Figure 9: Quantification of in vivo imaging data to monitor suicide gene therapy using hMultistem as cellular vehicles in the hU87
glioblastoma model. (a) Quantification of the volume of hypointense voxels in animals receiving SPIO labeled eGFP-fLuc-HSV-tk+
hMultistem cells indicates sufficient contrast to detect the therapeutic cells in the hU87 tumor model (sham (no cells): 𝑁 = 3, PBS treated:
𝑁 = 5, andGCV treated:𝑁 = 6). (b) Bioluminescent imaging data usingD-luciferin as a substrate for fLuc expressing hMultistemcells showed
that the stem cells were detectable through BLI. A decrease in stem cell viability was detected for both PBS and GCV treated animals, which
indicates that the stem cells are unable to survive well in the tumormicroenvironment. (c) Bioluminescent imaging data using coelenterazine-
h as a substrate for rLuc to investigate tumor viability indicated tumor growth in the sham operated and PBS treated group but not in the GCV
treated group. (d) Tumor volumemeasurements proved no statistical differences between shamoperated, PBS treated, orGCV treated animals
(green bar: hMultistem injection; red bar: duration of GCV/PBS treatment). (e) T
1
-weighted MRI pre- and postcontrast injection showed
BBB integrity loss in the hU87 tumor compared to the contralateral hemisphere and the extracranial muscle at all time points (𝑁 = 11).
Levels of significance are expressed as ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001.
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